TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A review in the Journal of the Endocrine Society says women with polyendocrine metabolic ovarian syndrome (PMOS), formerly called PCOS, may have greater risk of memory and brain changes associated with Alzheimer’s disease and dementia. The authors describe a possible association, not proof that PMOS independently causes dementia; insulin resistance and obesity may help explain the link.
A review published in the Journal of the Endocrine Society reports that women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), may be more likely to experience changes in memory, thinking and brain health linked to Alzheimer’s disease and dementia. The authors say the available evidence does not establish that PMOS itself causes these conditions, and suggest that insulin resistance, obesity and other metabolic problems may account for much of the apparent association.
The researchers reviewed existing studies identified through a PubMed search from its inception through October 2025. They concluded that people with PMOS may face increased risk of changes in memory and thinking, as well as alterations in brain structure and function that could be relevant to Alzheimer’s disease and related dementias. The work is a review of prior evidence, not a new clinical trial or a study that directly measured dementia risk in a newly recruited group.
The report describes mild but reproducible impairments in executive function and memory among people with PMOS, alongside reported structural and functional brain differences. The authors say these findings may point to pathways associated with Alzheimer’s and dementia, but they do not establish that those brain changes will lead to a diagnosis or show how large any individual’s risk might be.
PMOS affects an estimated 10% to 15% of women worldwide, according to the source report. It is associated with a range of health conditions, including diabetes, heart disease, stroke, depression, anxiety, infertility and endometrial cancer. The review’s authors say metabolic conditions common alongside PMOS—particularly insulin resistance and obesity—could mediate the possible connection with dementia-related outcomes.
Why Metabolic Health Matters
The review brings attention to a possible longer-term brain-health dimension of a syndrome already associated with several physical and mental health conditions. If future research confirms a relationship, it could help clinicians and researchers better understand which factors contribute to cognitive changes among people with PMOS. For now, the findings are a research signal, not evidence that a PMOS diagnosis means a person will develop Alzheimer’s disease or dementia.
The proposed role of metabolic comorbidities matters because it leaves open several explanations: cognitive differences could relate to PMOS itself, to conditions that often occur with it, or to interactions among multiple factors. Distinguishing these possibilities could guide future studies and clarify whether any observed risk is tied to the syndrome independently of obesity, insulin resistance or other health conditions.
The source report says PMOS can have lifelong effects and may also affect males in different ways. The review focuses on evidence relevant to women’s health and Alzheimer’s-related outcomes; it does not provide an individual risk estimate or recommend a new screening or treatment approach. People should discuss personal health concerns and decisions with a qualified health professional.
Probiotics for gut health in women
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From PCOS to PMOS Research
The condition was formerly referred to as polycystic ovary syndrome, or PCOS; the review uses the term polyendocrine metabolic ovarian syndrome, or PMOS. The report frames it as a condition with reproductive, endocrine and metabolic dimensions and notes its associations with a broad range of health issues.
The review, titled “Potential links between PCOS/PMOS and Alzheimer disease and related dementias,” was published in 2026 in the Journal of the Endocrine Society. Its authors include Mina Amiri and Armita Kakavand Hamidi of Tehran University of Medical Sciences, Ricardo Azziz and Richard P. Buyalos of the University of Alabama at Birmingham, and Daniel L. Farkas, who is affiliated with the Foundation for Research and Education Excellence and the University of Southern California. The work was funded by the Foundation for Research and Education Excellence.
““Current evidence suggests that any association between PMOS and Alzheimer’s disease and dementia is likely mediated by metabolic comorbidities, particularly insulin resistance and obesity, rather than an independent effect of PMOS itself.””
— Ricardo Azziz, study co-author and University of Alabama at Birmingham researcher
Limits of the Current Evidence
The review identifies a possible association, but the source material does not report a confirmed causal relationship, a quantified increase in dementia diagnoses, or an estimate of absolute risk for women with PMOS. It is also not clear from the report how much of the observed cognitive and brain-health evidence comes from studies that followed participants over time, or how consistently those studies accounted for metabolic conditions and other possible influences.
The authors say the evidence base has important gaps and calls for further research. The findings therefore cannot determine whether PMOS independently affects later dementia risk, whether metabolic conditions explain the association, or whether both processes contribute. They also do not establish that every person with PMOS has measurable cognitive impairment.
Research Needed to Test the Link
The review points to future research as the next step, particularly studies that can distinguish the effects of PMOS from those of insulin resistance, obesity and other related conditions. Research following people over time and using consistent measures of cognition and brain health could help clarify whether the reported differences predict later Alzheimer’s disease or dementia.
No follow-up study, clinical recommendation or specific timeline for new research is given in the source material. Until stronger evidence is available, the review should be read as a summary of a potential link and a call for further investigation, not as a diagnosis or a change in care guidance.
Key Questions
Does this review prove that PMOS causes Alzheimer’s disease?
No. The review describes a possible association. Its authors say metabolic conditions, including insulin resistance and obesity, may help explain the link, and the evidence does not establish that PMOS independently causes Alzheimer’s disease.
What did the researchers review?
The authors conducted a PubMed search through October 2025 and reviewed existing evidence on PMOS, formerly called PCOS, and Alzheimer’s disease or related dementias. This was a review, not a new clinical trial.
What symptoms or brain changes were discussed?
The report describes mild, reproducible differences in executive function and memory, as well as structural and functional brain alterations. It does not say these findings mean a person will develop dementia.
Should people with PMOS change their care because of this review?
The review does not set out new screening or treatment guidance. Anyone with questions about cognitive changes or PMOS-related health should discuss them with a qualified health professional.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
